Targeting non-malignant disorders with tyrosine kinase inhibitors

Nature Reviews Drug Discovery

Volumn 9, Issue 12, 2010, Pages 956-970

  Grimminger, Friedrich ^a,b   Schermuly, Ralph T ^b,c   Ghofrani, Hossein A ^a,b  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^c MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; 6,7 DIMETHYL 2 PHENYLQUINOXALINE; BEVACIZUMAB; BIBF 1120; CALCINEURIN INHIBITOR; DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; JANUS KINASE 3 INHIBITOR; LAPATINIB; LESTAURTINIB; METHOTREXATE; MIDOSTAURIN; N [4 METHYL 3 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINO]PHENYL]BENZAMIDE; NILOTINIB; PAZOPANIB; PLACEBO; PROSTANOID; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RANIBIZUMAB; SEMAXANIB; SORAFENIB; SU 5614; SUNITINIB; TANDUTINIB; UNCLASSIFIED DRUG; VATALANIB; VOTRIENT;

ACUTE GRAFT REJECTION; ACUTE GRANULOCYTIC LEUKEMIA; ATHEROSCLEROSIS; BRONCHIOLITIS OBLITERANS; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIOTOXICITY; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DIMERIZATION; DISEASE EXACERBATION; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCYTOSIS; FIBROSING ALVEOLITIS; GASTROINTESTINAL STROMAL TUMOR; GENE ACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; GLIOBLASTOMA; GLOMERULONEPHRITIS; GRAFT REJECTION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HUMAN; IMMUNOPRECIPITATION; IN-STENT RESTENOSIS; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; LUNG VASCULAR RESISTANCE; MELANOMA; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; RETINA MACULA DEGENERATION; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SARCOMA; SIGNAL TRANSDUCTION; SOLID TUMOR; SYSTEMIC SCLEROSIS; THYROID TUMOR; UBIQUITINATION; UPREGULATION;

ANIMALS; ATHEROSCLEROSIS; DRUG DELIVERY SYSTEMS; HUMANS; HYPERTENSION, PULMONARY; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 78649719727     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3297     Document Type: Review

References (234)

1. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 103, 211-225 (2000).
2. Hunter, T. The Croonian Lecture 1997. The phosphorylation of proteins on tyrosine: its role in cell growth and disease. Philos. Trans. R. Soc. Lond. B Biol. Sci. 353, 583-605 (1998).
3. Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912-1934 (2002).
4. Wang, F., Zeltwanger, S., Yang, I. C., Nairn, A. C. & Hwang, T. C. Actions of genistein on cystic fibrosis transmembrane conductance regulator channel gating. Evidence for two binding sites with opposite effects. J. Gen. Physiol. 111, 477-490 (1998).
5. Wong, W. S. & Leong, K. P. Tyrosine kinase inhibitors: a new approach for asthma. Biochim. Biophys. Acta 1697, 53-69 (2004).
6. Malhotra, S., Man, S. F. & Sin, D. D. Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin. Emerg. Drugs 11, 275-291 (2006).
7. Beales, I. L. & Calam, J. Stimulation of IL-8 production in human gastric epithelial cells by Helicobacter pylori, IL-1beta and TNF-alpha requires tyrosine kinase activity, but not protein kinase C. Cytokine 9, 514-520 (1997).
8. Ben-Bassat, H. Biological activity of tyrosine kinase inhibitors: novel agents for psoriasis therapy. Curr. Opin. Investig. Drugs 2,1539-1545 (2001).
9. Ben-Bassat, H. Tyrphostins that suppress the growth of human papilloma virus 16-immortalized human keratinocytes. J. Pharmacol. Exp. Ther. 290, 1442-1457 (1999).
10. Novogrodsky, A. et al. Prevention of lipopolysaccharide-induced lethal toxicity by tyrosine kinase inhibitors. Science 264,1319-1322 (1994).
11. Chappelow, A. V. & Kaiser, P. K. Neovascular age-related macular degeneration: potential therapies. Drugs 68,1029-1036 (2008).
12. Song, R. X. et al. Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells. J. Steroid Biochem. Mol. Biol. 11 8, 219-30 (2010).
13. Gschwind, A., Fischer, O. M. & Ullrich, A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nature Rev. Cancer 4, 361-370 (2004).
14. Hubbard, S. R. & Miller, W. T. Receptor tyrosine kinases: mechanisms of activation and signaling. Curr. Opin. Cell Biol. 19, 117-123 (2007).
15. Chen, H. et al. A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. Mol. Cell 27, 717-730 (2007).
16. Giehl, K., Skripczynski, B., Mansard, A., Menke, A. & Gierschik, P. Growth factor-dependent activation of the Ras-Raf-MEK-MAPK pathway in the human pancreatic carcinoma cell line PANC-1 carrying activated K-ras: implications for cell proliferation and cell migration. Oncogene 19, 2930-2942 (2000).
17. Krause, D. S. & Van Etten, R. A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353, 172-187 (2005).
18. Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182 (1987).
19. Arteaga, C. L. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J. Clin. Oncol. 19, S32-S40 (2001).
20. Witton, C. J., Reeves, J. R., Going, J. J., Cooke, T. G. & Bartlett, J. M. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J. Pathol. 200, 290-297 (2003).
21. Salomon, D. S., Brandt, R., Ciardiello, F. & Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19, 183-232 (1995).
22. Libermann, T. A. et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313, 144-147 (1985).
23. Olapade-Olaopa, E. O. et al. Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br. J. Cancer 82, 186-194 (2000).
24. Sainsbury, J. R., Farndon, J. R., Sherbet, G. V. & Harris, A. L. Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. Lancet 1, 364-366 (1985).
25. Ooi, A. et al. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod. Pathol. 17, 895-904 (2004).
26. Messa, C., Russo, F., Caruso, M. G. & Di, L. A. EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol. 37, 285-289 (1998).
27. Hida, T. et al. Gefitinib for the treatment of non-small-cell lung cancer. Expert Rev. Anticancer Ther. 9, 17-35 (2009).
28. Gorgoulis, V. et al. Expression of EGF, TGF-alpha and EGFR in squamous cell lung carcinomas. Anticancer Res. 12, 1183-1187 (1992).
29. Hermanson, M. et al. Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas. Cancer Res. 56, 164-171 (1996).
30. Matei, D. et al. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Cancer 113, 723-732 (2008).
31. Heinrich, M. C. et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299, 708-710 (2003).
32. Hirota, S. et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 125, 660-667 (2003).
33. Sjoblom, T. et al. Characterization of the chronic myelomonocytic leukemia associated TEL-PDGF βR fusion protein. Oncogene 18, 7055-7062 (1999).
34. Martinet, Y., Rom, W. N., Grotendorst, G. R., Martin, G. R. & Crystal, R. G. Exaggerated spontaneous release of platelet-derived growth factor by alveolar macrophages from patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 317, 202-209 (1987).
35. Kallio, E. A., Koskinen, P. K., Aavik, E., Buchdunger, E. & Lemstrom, K. B. Role of platelet-derived growth factor in obliterative bronchiolitis (chronic rejection) in the rat. Am. J. Respir. Crit. Care Med. 160, 1324-1332 (1999).
36. Tikkanen, J. M. et al. Role of platelet-derived growth factor and vascular endothelial growth factor in obliterative airway disease. Am. J. Respir. Crit. Care Med. 174, 1145-1152 (2006).
37. Ferns, G. A. et al. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 253, 1129-1132 (1991).
38. Schermuly, R. T. A. et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J. Clin. Invest. 11 5, 2811-2821 (2005).
39. Jackson, M. W., Bentel, J. M. & Tilley, W. D. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J. Urol. 157, 2323-2328 (1997).
40. Kang, M. A., Kim, K. Y., Seol, J. Y., Kim, K. C. & Nam, M. J. The growth inhibition of hepatoma by gene transfer of antisense vascular endothelial growth factor. J. Gene Med. 2, 289-296 (2000).
41. Takahashi, Y., Kitadai, Y., Bucana, C. D., Cleary, K. R. & Ellis, L. M. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 55, 3964-3968 (1995).
42. Takahashi, Y. et al. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin. Cancer Res. 2, 1679-1684 (1996).
43. Ferrara, N., Gerber, H. P. & LeCouter, J. The biology of VEGF and its receptors. Nature Med. 9, 669-676 (2003).
44. Chen, G. J. & Forough, R. Fibroblast growth factors, fibroblast growth factor receptors, diseases, and drugs. Recent Pat. Cardiovasc. Drug Discov. 1, 211-224 (2006).
45. Hartog, H., Wesseling, J., Boezen, H. M. & van der Graaf, W. T. The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur. J. Cancer 43, 1895-1904 (2007).
46. Levitzki, A. & Gazit, A. Tyrosine kinase inhibition: an approach to drug development. Science 267, 1782-1788 (1995).
47. Gontarewicz, A. & Brummendorf, T. H. Danusertib (formerly PHA-739358) -a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor. Recent Results Cancer Res. 184, 199-214 (2010).
48. Bain, J. et al. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408, 297-315 (2007).
49. Karaman, M. W. et al. A quantitative analysis of kinase inhibitor selectivity. Nature Biotechnol. 26, 127-132 (2008).
50. Nef, H. M., Mollmann, H., Hamm, C., Grimminger, F. & Ghofrani, H. A. Pulmonary hypertension: updated classification and management of pulmonary hypertension. Heart 96, 552-559 (2010).
51. Barst, R. J. et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. 334, 296-302 (1996).
52. Olschewski, H. et al. Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med. 347, 322-329 (2002).
53. Rubin, L. J. et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346, 896-903 (2002).
54. Galie, N. et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. 353, 2148-2157 (2005). (Pubitemid 41653106)
55. Humbert, M. et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur. Respir. J. 11, 554-559 (1998).
56. Wedgwood, S. et al. Fibroblast growth factor-2 expression is altered in lambs with increased pulmonary blood flow and pulmonary hypertension. Pediatr. Res. 61, 32-36 (2007).
57. Merklinger, S. L., Jones, P. L., Martinez, E. C. & Rabinovitch, M. Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation 11 2, 423-431 (2005).
58. Taraseviciene-Stewart, L. et al. Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 291, L668-L676 (2006).
59. Christou, H., Yoshida, A., Arthur, V., Morita, T. & Kourembanas, S. Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-induced pulmonary hypertension. Am. J. Respir. Cell. Mol. Biol. 18, 768-776 (1998).
60. Balasubramaniam, V. et al. Role of platelet-derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus. Am. J. Physiol. Lung Cell. Mol. Physiol. 284, L826-L833 (2003).
61. Cohen, M. H. et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res. 8, 935-942 (2002).
62. Buchdunger, E. et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56, 100-104 (1996).
63. Heinrich, M. C. et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96, 925-932 (2000).
64. Hunter, T. Treatment for chronic myelogenous leukemia: the long road to imatinib. J. Clin. Invest. 11 7, 2036-2043 (2007).
65. Perros, F. et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 178, 81-88 (2008).
66. Ghofrani, H. A., Seeger, W. & Grimminger, F. Imatinib for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 353, 1412-1413 (2005). (Pubitemid 41362714)
67. Patterson, K. C., Weissmann, A., Ahmadi, T. & Farber, H. W. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann. Intern. Med. 145, 152-153 (2006).
68. Souza, R., Sitbon, O., Parent, F., Simonneau, G. & Humbert, M. Long term imatinib treatment in pulmonary arterial hypertension. Thorax 61, 736 (2006).
69. Ghofrani, H. A. et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am. J. Respir. Crit. Care Med. 25 (2010).
70. Perros, F. et al. Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. Eur. Respir. J. 29, 462-468 (2007).
71. Mitani, Y. et al. Mast cell chymase in pulmonary hypertension. Thorax 54, 88-90 (1999).
72. Ushio-Fukai, M. et al. cAbl tyrosine kinase mediates reactive oxygen species- and caveolin-dependent AT1 receptor signaling in vascular smooth muscle: role in vascular hypertrophy. Circ. Res. 97, 829-836 (2005).
73. Daniels, C. E. et al. Imatinib mesylate inhibits the profibrogenic activity of TGFβ and prevents bleomycin-mediated lung fibrosis. J. Clin. Invest. 11 4, 1308-1316 (2004).
74. Kerkela, R. et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nature Med. 12, 908-916 (2006).
75. Fernandez, A. et al. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J. Clin. Invest. 11 7, 4044-4054 (2007).
76. Li, P., Oparil, S., Sun, J. Z., Thompson, J. A. & Chen, Y. F. Fibroblast growth factor mediates hypoxia-induced endothelin -a receptor expression in lung artery smooth muscle cells. J. Appl. Physiol. 95, 643-651 (2003).
77. Quinn, T. P., Schlueter, M., Soifer, S. J. & Gutierrez, J. A. Cyclic mechanical stretch induces VEGF and FGF-2 expression in pulmonary vascular smooth muscle cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 282, L897-L903 (2002).
78. Kwapiszewska, G. et al. Expression profiling of laser-microdissected intrapulmonary arteries in hypoxia-induced pulmonary hypertension. Respir. Res. 6,109 (2005).
79. Izikki, M. et al. Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. J. Clin. Invest. 11 9, 512-523 (2009).
80. +-ATPase activity in hippocampal neurons. Brain Res. 756, 205-214 (1997).
81. Jones, P. L. & Rabinovitch, M. Tenascin-C is induced with progressive pulmonary vascular disease in rats and is functionally related to increased smooth muscle cell proliferation. Circ. Res. 79, 1131-1142 (1996).
82. Jones, P. L., Cowan, K. N. & Rabinovitch, M. Tenascin-C, proliferation and subendothelial fibronectin in progressive pulmonary vascular disease. Am. J. Pathol. 150, 1349-1360 (1997).
83. Dahal, B. K. et al. Role of epidermal growth factor inhibition in experimental pulmonary hypertension. Am. J. Respir. Crit. Care Med. 181, 158-167 (2010).
84. Bublil, E. M. & Yarden, Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr. Opin. Cell Biol. 19, 124-134 (2007).
85. Gospodarowicz, D., Abraham, J. A. & Schilling, J. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. Proc. Natl Acad. Sci. USA 86, 7311-7315 (1989). (Pubitemid 19254450)
86. Tischer, E. et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 266, 11947-11954 (1991).
87. Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V. & Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306-1309 (1989).
88. Keck, P. J. et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246, 1309-1312 (1989).
89. Houck, K. A. et al. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol. 5, 1806-1814 (1991).
90. De Vries, C. et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255, 989-991 (1992).
91. Terman, B. I. et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 187, 1579-1586 (1992).
92. Soker, S., Takashima, S., Miao, H. Q., Neufeld, G. & Klagsbrun, M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92, 735-745 (1998).
93. Gluzman-Poltorak, Z., Cohen, T., Herzog, Y. & Neufeld, G. Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165 [corrected]. J. Biol. Chem. 275, 18040-18045 (2000).
94. Olofsson, B. et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc. Natl Acad. Sci. USA 95, 11709-11714 (1998).
95. Park, J. E., Chen, H. H., Winer, J., Houck, K. A. & Ferrara, N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem. 269, 25646-25654 (1994).
96. Eichmann, A. et al. Avian VEGF-C: cloning, embryonic expression pattern and stimulation of the differentiation of VEGFR2-expressing endothelial cell precursors. Development 125, 743-752 (1998).
97. Achen, M. G. et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc. Natl Acad. Sci. USA 95, 548-553 (1998).
98. Geiger, R. et al. Enhanced expression of vascular endothelial growth factor in pulmonary plexogenic arteriopathy due to congenital heart disease. J. Pathol. 191, 202-207 (2000).
99. Tuder, R. M. et al. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J. Pathol. 195, 367-374 (2001).
100. Taraseviciene-Stewart, L. et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J. 15, 427-438 (2001).
101. Taraseviciene-Stewart, L. et al. Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. Am. J. Respir. Crit. Care Med. 175, 1280-1289 (2007).
102. Kasahara, Y. et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J. Clin. Invest. 106, 1311-1319 (2000).
103. Tuder, R. M. et al. Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade. Am. J. Respir. Cell. Mol. Biol. 29, 88-97 (2003).
104. Voelkel, N. F., Vandivier, R. W. & Tuder, R. M. Vascular endothelial growth factor in the lung. Am. J. Physiol. Lung Cell. Mol. Physiol. 290, L209-L221 (2006).
105. Wong, W. K., Knowles, J. A. & Morse, J. H. Bone morphogenetic protein receptor type II C-terminus interacts with c-Src: implication for a role in pulmonary arterial hypertension. Am. J. Respir. Cell. Mol. Biol. 33, 438-446 (2005).
106. Aono, Y. et al. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am. J. Respir. Crit. Care Med. 171, 1279-1285 (2005).
107. Abdollahi, A. et al. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J. Exp. Med. 201, 925-935 (2005).
108. Vuorinen, K., Gao, F., Oury, T. D., Kinnula, V. L. & Myllarniemi, M. Imatinib mesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia. Exp. Lung Res. 33, 357-373 (2007).
109. Daniels, C. E. et al. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am. J. Respir. Crit. Care Med. 181, 604-610 (2010).
110. Chaudhary, N. I. et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur. Respir. J. 29, 976-985 (2007).
111. Hilberg, F. et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 68, 4774-4782 (2008).
112. Baroni, S. S. et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N. Engl. J. Med. 354, 2667-2676 (2006).
113. Ludwicka, A. et al. Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. J. Rheumatol. 22, 1876-1883 (1995).
114. Soria, A. et al. The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study. Dermatology 216, 109-117 (2008).
115. Sabnani, I. et al. A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatology 48, 49-52 (2009).
116. Kurogi, Y. Mesangial cell proliferation inhibitors for the treatment of proliferative glomerular disease. Med. Res. Rev. 23, 15-31 (2003).
117. Floege, J. et al. Infusion of platelet-derived growth factor or basic fibroblast growth factor induces selective glomerular mesangial cell proliferation and matrix accumulation in rats. J. Clin. Invest. 92, 2952-2962 (1993).
118. Iyoda, M. et al. Imatinib suppresses cryoglobulinemia and secondary membranoproliferative glomerulonephritis. J. Am. Soc. Nephrol. 20, 68-77 (2009).
119. Zoja, C. et al. Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. Kidney Int. 70, 97-103 (2006).
120. Gilbert, R. E. et al. PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int. 59, 1324-1332 (2001).
121. Hirai, T. et al. PDGF receptor tyrosine kinase inhibitor suppresses mesangial cell proliferation involving STAT3 activation. Clin. Exp. Immunol. 144, 353-361 (2006).
122. Stanczyk, J., Ospelt, C. & Gay, S. Is there a future for small molecule drugs in the treatment of rheumatic diseases? Curr. Opin. Rheumatol. 20, 257-262 (2008).
123. Milici, A. J. et al. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res. Ther. 10, R14 (2008).
124. Kremer, J. M. et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690550 versus placebo. Arthritis Rheum. 60,1895-1905 (2009).
125. Coombs, J. H. et al. Improved pain, physical functioning, and health status in rheumatoid arthritis patients treated with CP-690550, an orally active Janus kinase (JAK) inhibitor: results from a randomized, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 8, 413-416 (2009).
126. Weinblatt, M. E. et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid Arthritis. N. Engl. J. Med. 363, 1303-1312 (2010).
127. Tebib, J. et al. Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study. Arthritis Res. Ther. 11, R95 (2009).
128. Konda, V. R., Desai, A., Darland, G., Bland, J. S. & Tripp, M. L. META060 inhibits osteoclastogenesis and matrix metalloproteinases in vitro and reduces bone and cartilage degradation in a mouse model of rheumatoid arthritis. Arthritis Rheum. 62,1683-1692 (2010).
129. Gourishankar, S., Turner, P. & Halloran, P. New developments in immunosuppressive therapy in renal transplantation. Expert Opin. Biol. Ther. 2, 483-501 (2002).
130. Kawamura, M. et al. Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. Proc. Natl Acad. Sci. USA 91, 6374-6378 (1994).
131. Deuse, T. et al. Novel immunosuppression: R348, a JAK3- and Syk-inhibitor attenuates acute cardiac allograft rejection. Transplantation 85, 885-892 (2008).
132. Changelian, P. S. et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302, 875-878 (2003).
133. Borie, D. C. et al. Immunosuppression by the JAK3 inhibitor CP-690550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates. Transplantation 79, 791-801 (2005).
134. Kudlacz, E. et al. The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am. J. Transplant 4, 51-57 (2004).
135. Podder, H. & Kahan, B. D. Janus kinase 3: a novel target for selective transplant immunosupression. Expert Opin. Ther. Targets 8, 613-629 (2004).
136. Karck, M. et al. Inhibition of aortic allograft vasculopathy by local delivery of platelet-derived growth factor receptor tyrosine-kinase blocker AG-1295. Transplantation 74,1335-1341 (2002).
137. Burchat, A. et al. Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection. Bioorg. Med. Chem. Lett. 16, 118-122 (2006).
138. Force, T., Krause, D. S. & Van Etten, R. A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nature Rev. Cancer 7, 332-344 (2007). (Pubitemid 46652481)
139. Druker, B. J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408-2417 (2006).
140. Hochhaus, A. et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 111, 1039-1043 (2008).
141. Verweij, J. et al. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analyis of EORTC-ISG-AGITG study 62005. Eur. J. Can. 43, 974-978 (2007).
142. Perik, P. J. et al. Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity. Ann. Oncol. 19, 359-361 (2008).
143. Ribeiro, A. L. et al. An evaluation of the cardiotoxicity of imatinib mesylate. Leukemia Res. 32, 1809-1814 (2008).
144. Will, Y. et al. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol. Sci. 106, 153-161 (2008).
145. Torsoni, A. S. et al. Focal adhesion kinase is activated and mediates the early hypertrophic response to stretch in cardiac myocytes. Circ. Res. 93, 140-147 (2003).
146. Nadruz, W. et al. Focal adhesion kinase mediates MEF2 and c-Jun activation by stretch: role in the activation of the cardiac hypertrophic genetic program. Cardiovasc. Res. 68, 87-97 (2005).
147. Marin, T. M. et al. Shp2 negatively regulates growth in cardiomyocytes by controlling focal adhesion kinase/src and mtor pathways. Circ. Res. 103, 813-824 (2008).
148. Takeishi, Y. et al. Src and multiple map kinase activation in cardiac hypertrophy and congestive heart failure under chronic pressure-overload: comparison with acute mechanical stretch. J. Mol. Cell. Cardiol. 33, 1637-1648 (2001).
149. Onan, D., Pipolo, L., Yang, E., Hannan, R. D. & Thomas, W. G. Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. Mol. Endocrinol. 18, 2344-2354 (2004).
150. Dwyer, J. P . et al. Myocardial gene expression associated with genetic cardiac hypertrophy in the absence of hypertension. Hypertens. Res. 31, 941-955 (2008).
151. Oudit, G. Y. & Penninger, J. M. Cardiac regulation by phosphoinositide 3-kinases and PTEN. Cardiovasc. Res. 8, 250-260 (2009).
152. Beckles, D. L., Mascareno, E. & Siddiqui, M. A. Q. Inhibition of Jak2 phosphorylation attenuates pressure overload cardiac hypertrophy. Vascul. Pharmacol. 45, 350-357 (2006).
153. Klein, M. et al. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation 11 8, 2081-2090 (2008).
154. Kagiyama, S., Qian, K., Kagiyama, T. & Phillips, M. I. Antisense to epidermal growth factor receptor prevents the development of left ventricular hypertrophy. Hypertension 41, 824-829 (2003).
155. Smith, N. J., Chan, H. W., Osborne, J. E., Thomas, W. G. & Hannan, R. D. Hijacking epidermal growth factor receptors by angiotensin II: new possibilities for understanding and treating cardiac hypertrophy. Cell. Mol. Life Sci. 61, 2695-2703 (2004).
156. Park, Y. H. et al. BNP as a marker of the heart failure in the treatment of imatinib mesylate. Cancer Lett. 243, 16-22 (2006).
157. Hazarika, M. et al. Tasigna for chronic and accelerated phase Philadelphia chromosome -positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin. Cancer Res. 14, 5325-5331 (2008).
158. Brave, M. et al. Sprycel for chronic myeloid leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin. Cancer Res. 14, 352-359 (2008).
159. Chu, T. F. et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370, 2011-2019 (2007).
160. Khakoo, A. Y. et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 11 2, 2500-2508 (2008).
161. Telli, M. L., Witteles, R. M., Fisher, G. A. & Srinivas, S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann. Oncol. 19, 1613-1618 (2008).
162. Russo, P. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma: Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M, Schmidinger H. Urologic Oncol. Semin. Original Invest. 27,103-104 (2009).
163. Schmidinger, M. et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 26, 5204-5212 (2008).
164. Kenagy, R. D., Hart, C. E., Stetler-Stevenson, W. G.& Clowes, A. W. Primate smooth muscle cell migration from aortic explants is mediated by endogenous platelet-derived growth factor and basic fibroblast growth factor acting through matrix metalloproteinases 2 and 9. Circulation 96, 3555-3560 (1997).
165. Banai, S. et al. Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries. Cardiovasc. Res. 64, 165-171 (2004).
166. Zohlnhofer, D. et al. A randomized, double-blind, placebo-controlled trial on restenosis prevention by the receptor tyrosine kinase inhibitor imatinib. J. Am. Coll. Cardiol. 46, 1999-2003 (2005).
167. Hacker, T. A., Griffin, M. O., Guttormsen, B., Stoker, S. & Wolff, M. R. Platelet-derived growth factor receptor antagonist STI571 (imatinib mesylate) inhibits human vascular smooth muscle proliferation and migration in vitro but not in vivo. J. Invasive Cardiol. 19, 269-274 (2007).
168. Serruys, P. W. et al. Effect of an anti-PDGF-beta-receptor-blocking antibody on restenosis in patients undergoing elective stent placement. Int. J. Cardiovasc. Intervent. 5, 214-222 (2003).
169. Klocke, R., Hasib, L. & Nikol, S. Recently patented applications of homologous cellular and extracellular agents as therapeutics or targets for the prevention of restenosis post-angioplasty. Recent Pat. Cardiovasc. Drug Discov. 1, 57-66 (2006).
170. Ross, R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362, 801-809 (1993).
171. Hansson, G. K., Jonasson, L., Seifert, P. S. & Stemme, S. Immune mechanisms in atherosclerosis. Arteriosclerosis 9, 567-578 (1989).
172. Libby, P., Warner, S. J., Salomon, R. N. & Birinyi, L. K. Production of platelet-derived growth factor-like mitogen by smooth-muscle cells from human atheroma. N. Engl. J. Med. 318,1493-1498 (1988).
173. Misiakos, E. P. et al. Expression of PDGF-A, TGFb and VCAM-1 during the developmental stages of experimental atherosclerosis. Eur. Surg. Res. 33, 264-269 (2001).
174. Martinet, Y. et al. Activated human monocytes express the c-sis proto-oncogene and release a mediator showing PDGF-like activity. Nature 319, 158-160 (1986).
175. Uchida, K., Sasahara, M., Morigami, N., Hazama, F. & Kinoshita, M. Expression of platelet-derived growth factor B-chain in neointimal smooth muscle cells of balloon injured rabbit femoral arteries. Atherosclerosis 124, 9-23 (1996).
176. Thomas, J. A. et al. PDGF-DD, a novel mediator of smooth muscle cell phenotypic modulation, is upregulated in endothelial cells exposed to atherosclerosis-prone flow patterns. Am. J. Physiol. Heart Circ. Physiol. 296, H442-H452 (2009).
177. Karvinen, H. et al. PDGF-C and -D and their receptors PDGFR-alpha and PDGFR-beta in atherosclerotic human arteries. Eur. J. Clin. Invest. 39, 320-327 (2009).
178. Rubin, K. et al. Induction of B-type receptors for platelet-derived growth factor in vascular inflammation: possible implications for development of vascular proliferative lesions. Lancet 1, 1353-1356 (1988).
179. Leppanen, O. et al. Intimal hyperplasia recurs after removal of PDGF-AB and -BB inhibition in the rat carotid artery injury model. Arterioscler. Thromb. Vasc. Biol. 20, E89-E95 (2000).
180. Banai, S. et al. PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine. Circulation 97, 1960-1969 (1998).
181. Yamasaki, Y. et al. Weekly dosing with the platelet-derived growth factor receptor tyrosine kinase inhibitor SU9518 significantly inhibits arterial stenosis. Circ. Res. 88, 630-636 (2001).
182. Giese, N. A. et al. The role of alpha and beta platelet-derived growth factor receptor in the vascular response to injury in nonhuman primates. Arterioscler. Thromb. Vasc. Biol. 19, 900-909 (1999).
183. Hart, C. E. et al. PDGFbeta receptor blockade inhibits intimal hyperplasia in the baboon. Circulation 99, 564-569 (1999).
184. Bilder, G. et al. Restenosis following angioplasty in the swine coronary artery is inhibited by an orally active PDGF-receptor tyrosine kinase inhibitor, RPR101511A. Circulation 99,103292-103299 (1999).
185. Sihvola, R. et al. Prevention of cardiac allograft arteriosclerosis by protein tyrosine kinase inhibitor selective for platelet-derived growth factor receptor. Circulation 99, 2295-2301 (1999). (Pubitemid 29201137)
186. Sano, H. et al. Functional blockade of platelet-derived growth factor receptor-beta but not of receptor-alpha prevents vascular smooth muscle cell accumulation in fibrous cap lesions in apolipoprotein E-deficient mice. Circulation 103, 2955-2960 (2001).
187. Kozaki, K. et al. Blockade of platelet-derived growth factor or its receptors transiently delays but does not prevent fibrous cap formation in ApoE null mice. Am. J. Pathol. 161, 1395-1407 (2002).
188. Jawien, A., Bowen-Pope, D. F., Lindner, V., Schwartz, S. M. & Clowes, A. W. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J. Clin. Invest. 89, 507-511 (1992).
189. Nabel, E. G. et al. Recombinant platelet-derived growth factor B gene expression in porcine arteries induce intimal hyperplasia in vivo. J. Clin. Invest. 91, 1822-1829 (1993).
190. Newton, C. S. et al. Platelet-derived growth factor receptor-beta (PDGFR-beta) activation promotes its association with the low density lipoprotein receptor-related protein (LRP). Evidence for co-receptor function. J. Biol. Chem. 280, 27872-27878 (2005).
191. Boucher, P. et al. Platelet-derived growth factor mediates tyrosine phosphorylation of the cytoplasmic domain of the low density lipoprotein receptor-related protein in caveolae. J. Biol. Chem. 277, 15507-15513 (2002).
192. Boucher, P., Gotthardt, M., Li, W. P., Anderson, R. G. & Herz, J. LRP: role in vascular wall integrity and protection from atherosclerosis. Science 300, 329-332 (2003).
193. Boucher, P. et al. LRP1 functions as an atheroprotective integrator of TGFbeta and PDFG signals in the vascular wall: implications for Marfan syndrome. PLoS One 2, e448 (2007).
194. Takayama, Y., P, Anderson, R. G. & Herz, J. Low density lipoprotein receptor-related protein 1 (LRP1) controls endocytosis and c-CBL-mediated ubiquitination of the platelet-derived growth factor receptor beta (PDGFR beta). J. Biol. Chem. 280, 18504-18510 (2005).
195. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
196. Folkman, J. Angiogenesis: an organizing principle for drug discovery? Nature Rev. Drug Discov. 6, 273-286 (2007). (Pubitemid 46505878)
197. Masri, F. A. et al. Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 293, L548-L554 (2007).
198. Tuder, R. M. & Voelkel, N. F. Plexiform lesion in severe pulmonary hypertension: association with glomeruloid lesion. Am. J. Pathol. 159, 382-383 (2001).
199. Yeager, M. E., Halley, G. R., Golpon, H. A., Voelkel, N. F. & Tuder, R. M. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ. Res. 88, E2-E11 (2001).
200. Warburg, O. On Metabolism of Tumors. (Constable, London, 1930).
201. Xu, W. et al. Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proc. Natl Acad. Sci. USA 104, 1342-1347 (2007).
202. Zimmermann, G. R., Lehar, J. & Keith, C. T. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today 12, 34-42 (2007).
203. Keith, C. T., Borisy, A. A. & Stockwell, B. R. Multicomponent therapeutics for networked systems. Nature Rev. Drug Discov. 4, 71-78 (2005).
204. Belloc, F. et al. The stem cell factor-c-KIT pathway must be inhibited to enable apoptosis induced by BCR-ABL inhibitors in chronic myelogenous leukemia cells. Leukemia 23, 679-685 (2009).
205. Sleijfer, S., Wiemer, E. & Verweij, J. Drug Insight: gastrointestinal stromal tumors (GIST) -the solid tumor model for cancer-specific treatment. Nature Clin. Pract. Oncol. 5, 102-111 (2008).
206. Mendez, M. & LaPointe, M. C. PGE2-induced hypertrophy of cardiac myocytes involves EP4 receptor-dependent activation of p42/44 MAPK and EGFR transactivation. Am. J. Physiol. Heart Circ. Physiol. 288, H2111-H2117 (2005).
207. Ruwhof, C. & Van Der Laarse, A. Mechanical stress-induced cardiac hypertrophy: mechanisms and signal transduction pathways. Cardiovasc. Res. 47, 23-37 (2000).
208. Martinelli, G., Soverini, S., Iacobucci, I. & Baccarani, M. Intermittent targeting as a tool to minimize toxicity of tyrosine kinase inhibitor therapy. Nature Clin. Pract. Oncol. 6, 68-69 (2009).
209. Heinrich, M. C. et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J. Clin. Oncol. 26, 5360-5367 (2008).
210. Weisberg, E. et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7, 129-141 (2005).
211. O'Farrell, A. M. et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101, 3597-3605 (2003).
212. Motzer, R. J. et al. Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. Clin. Genitourin. Cancer 7, 28-33 (2009).
213. Faivre, S. et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol. 10, 794-800 (2009).
214. Wilhelm, S. M. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109 (2004).
215. Cheng, A. L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25-34 (2009).
216. Ferry, D. R. et al. A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin. Cancer Res. 13, 5869-5875 (2007).
217. Janmaat, M. L. A. et al. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J. Clin. Oncol. 24, 1612-1619 (2006).
218. Smolich, B. D. et al. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood 97, 1413-1421 (2001).
219. Fury, M. G. et al. A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers. Invest. New Drugs 25, 165-172 (2007).
220. Fiedler, W. et al. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 102, 2763-2767 (2003).
221. Weisberg, E. et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 1, 433-443 (2002).
222. Stone, R. M. et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 105, 54-60 (2005).
223. Chan, E. et al. A phase I trial of CEP-701 and gemcitabine in patients with advanced adenocarcinoma of the pancreas. Invest. New Drugs 26, 241-247 (2008).
224. Knapper, S. et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 108, 3262-3270 (2006).
225. Cheng, Y. & Paz, K. Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications. IDrugs 11, 46-56 (2008).
226. Kelly, L. M. et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell 1, 421-432 (2002).
227. Moreno-Vinasco, L. et al. Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiol. Genomics 33, 278-291 (2008).
228. Gomberg-Maitland, M. et al. A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension. Clin. Pharmacol. Ther. 87, 303-310 (2010).
229. Nagaoka, I., Trapnell, B. C. & Crystal, R. G. Upregulation of platelet-derived growth factor-A and -B gene expression in alveolar macrophages of individuals with idiopathic pulmonary fibrosis. J. Clin. Invest. 85, 2023-2027 (1990).
230. Kikuchi, K. et al. Serum concentrations of vascular endothelial growth factor in collagen diseases. Br. J. Dermatol. 139, 1049-1051 (1998).
231. Krebs, R. et al. Vascular endothelial growth factor plays a major role in development of experimental obliterative bronchiolitis. Transplant Proc. 38, 3266-3267 (2006).
232. Miller, J. W. Vascular endothelial growth factor and ocular neovascularization. Am. J. Pathol. 151, 13-23 (1997).
233. Rosenfeld, P. J. et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355, 1419-1431 (2006).
234. Donahue, S. P., Recchia, F. & Sternberg, P. Jr. Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial. Am. J. Ophthalmol. 150, 287 (2010).